06 May 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury After Massive Burns
Wojciech Klimm
1ABCDEFG*, Katarzyna Szamotulska 2ABCDEF, Marek Karwański 3CDE, Zbigniew Bartoszewicz4ABCDE, Wojciech Witkowski5ABCDE, Tomasz Rozmyslowicz6DEF, Stanisław Niemczyk 1ABCDEFG
DOI: 10.12659/MSM.943500
Med Sci Monit 2024; 30:e943500
Table 3 Estimated means of TIMP-1-4 parameter concentrations with acute kidney injury status and the number of days from injury (GLMM model).
| Overall effectsP values | Days from injury | Mean (95% CI) | Ratio of Means | P value | ||
|---|---|---|---|---|---|---|
| AKI status (ng/mL) | Non-AKI status (ng/mL) | |||||
| sTIMP1* | AKI status:=0.216Days from injury:=0.100Interaction term:=0.394 | 1 | 351.32 (274.26–450.03) | 214.52 (123.86–371.53) | 1.64 | 0.091 |
| 2 | 315.97 (242.69–411.38) | 249.97 (203.53–307.02) | 1.26 | 0.105 | ||
| 3 | 229.02 (171.26–306.27) | 230.05 (192.69–274.65) | 1.00 | 0.977 | ||
| 4 | 217.38 (122.85–384.63) | 224.22 (185.20–271.46) | 0.97 | 0.916 | ||
| 5 | 228.70 (132.45–394.89) | 208.57 (163.15–266.64) | 1.10 | 0.743 | ||
| uTIMP1 | AKI status:= 0.037Days from injury:=0.268Interaction term:=0.230 | 1 | 205.29 (89.19–472.48) | 13.14 (1.50–115.04) | 15.63 | 0.021 |
| 2 | 44.19 (18.08–108.03) | 38.36 (19.17–76.76) | 1.15 | 0.802 | ||
| 3 | 34.20 (14.75–79.31) | 14.61 (8.74–24.44) | 2.34 | 0.088 | ||
| 4 | 18.74 (5.32–65.96) | 18.42 (10.39–32.68) | 1.02 | 0.980 | ||
| 5 | 24.31 (6.82–86.63) | 18.59 (8.09–42.73) | 1.31 | 0.725 | ||
| sTIMP2** | AKI status:=0.441Days from injury:=0.231Interaction term:=0.503 | 1 | 110.74 (98.62–124.34) | 88.88 (66.20–119.33) | 1.25 | 0.167 |
| 2 | 108.53 (95.86–122.87) | 99.72 (90.60–109.75) | 1.09 | 0.271 | ||
| 3 | 94.86 (83.55–107.72) | 96.75 (89.92–104.10) | 0.98 | 0.786 | ||
| 4 | 90.72 (73.66–111.74) | 97.95 (90.14–106.43) | 0.93 | 0.492 | ||
| 5 | 89.96 (72.8–111.18) | 88.78 (79.07–99.67) | 1.01 | 0.912 | ||
| uTIMP2 | AKI status:=0.222Days from injury:=0.053Interaction term:=0.903 | 1 | 228.26 (54.82–950.53) | 59.00 (1.36–2569.81) | 3.87 | 0.506 |
| 2 | 58.29 (12.49–272.09) | 49.27 (14.94–162.51) | 1.18 | 0.864 | ||
| 3 | 448.88 (107.79–1869.34) | 121.11 (50.95–287.90) | 3.71 | 0.122 | ||
| 4 | 52.63 (5.96–465.05) | 31.10 (11.74–82.42) | 1.69 | 0.662 | ||
| 5 | 45.57 (5.16–402.70) | 32.32 (7.76–134.60) | 1.41 | 0.793 | ||
| sTIMP3 | AKI status:<0.001Days from injury:=0.563Interaction term:=0.489 | 1 | 54.5 (44.84–66.26) | 27.76 (16.70–46.17) | 1.96 | 0.016 |
| 2 | 53.96 (43.76–66.53) | 38.65 (32.85–45.47) | 1.40 | 0.013 | ||
| 3 | 45.65 (37.49–55.59) | 38.22 (33.89–43.11) | 1.19 | 0.127 | ||
| 4 | 50.97 (37.95–68.45) | 41.89 (36.47–48.12) | 1.22 | 0.232 | ||
| 5 | 50.81 (37.73–68.43) | 36.27 (29.84–44.09) | 1.40 | 0.062 | ||
| sTIMP4 | AKI status:=0.074Days from injury:=0.560Interaction term:=0.115 | 1 | 4.31 (3.18–5.83) | 1.74 (0.85–3.54) | 2.48 | 0.019 |
| 2 | 3.20 (2.33–4.38) | 2.12 (1.65–2.73) | 1.51 | 0.028 | ||
| 3 | 2.71 (1.97–3.71) | 2.22 (1.81–2.74) | 1.22 | 0.266 | ||
| 4 | 2.02 (1.32–3.10) | 2.44 (1.94–3.05) | 0.83 | 0.416 | ||
| 5 | 1.98 (1.26–3.10) | 2.00 (1.48–2.72) | 0.99 | 0.957 | ||
| * Patients 33 and 11 were deleted from the analysis for having extreme values (>3*IQR) in all points of observation. ** Patient 33 was deleted from the analysis for having extreme values (>3*IQR) in all points of observation. GLMM – generalized linear mixed models; TIMP 1–4 – tissue inhibitor of metalloproteinases 1–4; s – blood serum; u – urine; AKI – acute kidney injury. | ||||||